TAIHO PHARMA

We strive to
improve human
health and contribute
to a society enriched
by smiles

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

February 27, 2020

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences' Anti-PD-1 Antibody in Asia
January 06, 2020

Taiho, Astex and MSD Establish Strategic Oncology Collaboration
December 09, 2019

Taiho Pharmaceutical's Development of a Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) Selected for AMED's CiCLE Program
December 06, 2019

MSD and Taiho Pharmaceutical terminate co-promotion contract for anti-PD-1 antibody/anti-cancer drug KEYTRUDA^® In Japan（PDF：163.1 KB）
October 28, 2019

Taiho Pharmaceutical Greenhouse Gas Emissions Reduction Targets Earn Science Based Targets (SBT) Initiative Certification

Information

July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）